SEC Form 4 · accession 0001437749-26-022631
Monopar Therapeutics · MNPR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Quan Anh Vu
Officer — Chief Financial Officer
Period of report
Jun 30, 2026
Accepted (ET)
Jul 2, 2026 · 7:38 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001645469
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 30, 2026 | M | 1,228 | — | A | 2,728 | D | |
| Common StockF2 | Jun 30, 2026 | F | 507 | $92.59 | D | 2,221 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitF1,F3 | — | Jun 30, 2026 | M | 1,228 | D | — | — | Common Stock | 1,228 | 8,598 | D |
Explanation of responses
- F1Represents shares acquired on vesting and settlement of restricted stock units.
- F2Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units.
- F3On December 2, 2025, the reporting person was granted 9,826 restricted stock units, vesting 6/48ths (1,228) on June 30, 2026, and 3/48ths (614 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2029. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.